How comparing works here
How do I compare two companies?
Type the tickers into the box above — up to five at once. Every row is read from the companies' own annual filings, so a comparison shows the same measure computed the same way for each of them rather than whatever each company chose to highlight.
Can I compare an ETF with a stock?
Yes, and the table changes to suit. Two funds are compared on cost, income, spread and record, because revenue growth and debt mean nothing for a fund. A fund against a company shows only what both of them have.
Side by side
Compare
Put up to 4 companies, funds, commodities or coins next to each other — health, valuation, growth and performance.
Every row is computed the same way for every column, from each company's own annual filing, so a comparison is not a collection of whichever figures each of them chose to put in a press release. Funds are compared on what a fund is actually judged on: cost, income, spread and record.
Relative performance
Rebased so every symbol starts at 0%
Loading price history…
Side by side
Latest annual figures from each company's filings
| Metric | NTRANatera, Inc. | AMGNAMGEN INC | GILDGILEAD SCIENCES, INC. | VRTXVERTEX PHARMACEUTICALS INC / MA | Median of the restexcluding NTRA |
|---|---|---|---|---|---|
| Type | Company | Company | Company | Company | |
| Price | $401.37▼ 12.01 (2.91%) | $438.34▼ 0.60 (0.14%) | $157.19▲ 3.62 (2.36%) | $524.52▲ 9.87 (1.92%) | |
| Health scoreComposite of profitability, growth, debt and accounting quality. | 4.7/10 | 8.0/10 | 9.0/10 | 8.7/10 | 8.7/10 |
| Market value | $56.07B | $236.18B | $195.07B | $133.22B | |
| Revenue | $2.31B | $36.75B | $29.44B | $12.00B | |
| Profit | -$208.2M | $7.71B | $8.51B | $3.95B | |
| Revenue growthChange in sales versus the prior year. | 35.9% | 10.0% | 2.4% | 8.9% | 8.9% |
| Gross marginShare of sales left after the direct cost of producing them. | — | 67.2% | 78.8% | 86.2% | 78.8% |
| Operating marginShare of sales left after running the business, before interest and tax. | -13.4% | 24.7% | 34.0% | 34.8% | 34.0% |
| Profit marginProfit kept from each dollar of sales. | -9.0% | 21.0% | 28.9% | 32.9% | 28.9% |
| Free cash flow marginCash left after capital spending, as a share of sales. | 4.7% | 22.0% | 32.1% | 26.6% | 26.6% |
| Return on equityProfit against the owners' stake in the company. | -12.2% | 89.1% | 37.5% | 21.2% | 37.5% |
| Return on invested capital (approx.)Operating profit after tax against equity plus debt, less cash. Cash here excludes short-term investments, so this runs low for cash-rich companies. | -34.2% | 14.4% | 21.7% | 26.2% | 21.7% |
| P/E ratioPrice paid per dollar of annual profit. | — | 30.63x | 22.92x | 33.70x | 30.63x |
| EV / EBITDA (approx.)Market value plus debt less cash, against operating profit before depreciation. Cash excludes short-term investments, so this runs high for cash-rich companies. | — | 19.77x | 20.44x | — | 20.11x |
| Price to book | 32.74x | 27.28x | 8.59x | 7.14x | 8.59x |
| Debt to equityTotal liabilities compared with owners' stake. | 0.40x | 9.46x | 1.60x | 0.37x | 1.60x |
| Piotroski F-ScoreNine checks of financial strength. Higher is stronger. | 2/7 | 8/9 | 8/9 | 6/8 | 8.0 |
| Bankruptcy riskAltman Z-Score zone. | distress | grey | safe | safe |
How NTRA compares with the others
- NTRA's operating margin of -13.4% is lower than the median of the other companies selected (34.0%).
- Its revenue grew faster than the median of the other companies selected: 35.9% against 8.9%.
- It has no P/E to set against theirs, because it did not make a profit.
- Its liabilities are lower relative to equity than the median of the other companies selected: 0.4x against 1.6x.
Measured against the other companies entered, from each one's latest annual filing. A difference describes the companies; it does not rank them.